GLP1-T

What is a GLP-1/GIP dual agonist?

GIP and GLP-1 are the two incretin hormones — gut peptides that amplify insulin secretion after a meal. For decades GIP was considered the less useful of the two; that view changed when unimolecular peptides activating both receptors were shown, in animal and then clinical research, to produce effects beyond GLP-1 agonism alone. GLP1-T supplies a dual agonist of this class in a research format. It is the counterpart to the single-receptor GLP1-R.

What are dual incretin agonists studied for in research?

• Food-intake and preference models. Rodent work reported that a dual agonist selectively reduced preference for fat [1].
• Thermogenesis. A 2022 study described a thermogenic-like amino-acid signature in brown adipose tissue [2].
• Proteomics and next-generation agonists. Plasma-proteome profiling of dual agonism [3] and triple GLP-1/GIP/glucagon agonists [4] show where the field is heading; long-acting GIPR-selective agonists are now in clinical study too [5].

Animal, proteomic and clinical-pharmacology findings on the class. The research-grade material sold here is not a drug and is not for human use.

GLP1-T vs GLP1-R

One receptor versus two. The full comparison, including what the GIP component adds in the research literature, is in GLP-1 vs GLP-1/GIP dual agonist research.

Specifications and documentation

Identity by mass spectrometry (expected 4813.5 g/mol), purity by HPLC, batch-specific COA in every order. Store refrigerated and away from light, capped between uses. How to read the COA →

GLP1-T — frequently asked

Further reading

• GLP-1 vs GLP-1/GIP Dual Agonist Research: What the GIP Receptor Adds — Single-receptor incretin agonism has a two-decade literature; dual agonism has rewritten part of it in five years. Here is the comparison for researchers.
• Lyophilized Vial vs Pre-Filled Pen: Choosing a Research Format — Nine catalog compounds ship as vials, five as pens. The choice is about flexibility versus consistency, not quality.